Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Interest Expenses (2016 - 2025)

Abeona Therapeutics (ABEO) has 14 years of Interest Expenses data on record, last reported at $901000.0 in Q3 2025.

  • For Q3 2025, Interest Expenses fell 18.24% year-over-year to $901000.0; the TTM value through Sep 2025 reached $3.9 million, up 21.73%, while the annual FY2024 figure was $4.2 million, 906.7% up from the prior year.
  • Interest Expenses reached $901000.0 in Q3 2025 per ABEO's latest filing, down from $957000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $1.5 million in Q2 2021 and bottomed at $53000.0 in Q4 2021.
  • Average Interest Expenses over 5 years is $631105.3, with a median of $683000.0 recorded in 2021.
  • Peak YoY movement for Interest Expenses: tumbled 96.18% in 2021, then soared 949.52% in 2024.
  • A 5-year view of Interest Expenses shows it stood at $53000.0 in 2021, then surged by 235.85% to $178000.0 in 2022, then tumbled by 38.76% to $109000.0 in 2023, then skyrocketed by 892.66% to $1.1 million in 2024, then fell by 16.73% to $901000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $901000.0 in Q3 2025, $957000.0 in Q2 2025, and $998000.0 in Q1 2025.